Analytical Data
-
基因名
CHRNa4
- Application
-
别名
CHRNa4；NACRA4；Neuronal acetylcholine receptor subunit alpha-4
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P43681
-
表达区间
1-627aa
-
氨基酸序列
MELGGPGAPRLLPPLLLLLGTGLLRASSHVETRAHAEERLLKKLFSGYNKWSRPVANISDVVLVRFGLSIAQLIDVDEKNQMMTTNVWVKQEWHDYKLRWDPADYENVTSIRIPSELIWRPDIVLYNNADGDFAVTHLTKAHLFHDGRVQWTPPAIYKSSCSIDVTFFPFDQQNCTMKFGSWTYDKAKIDLVNMHSRVDQLDFWESGEWVIVDAVGTYNTRKYECCAEIYPDITYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSECGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPRTHTMPTWVRRVFLDIVPRLLLMKRPSVVKDNCRRLIESMHKMASAPRFWPEPEGEPPATSGTQSLHPPSPSFCVPLDVPAEPGPSCKSPSDQLPPQQPLEAEKASPHPSPGPCRPPHGTQAPGLAKARSLSVQHMSSPGEAVEGGVRCRSRSIQYCVPRDDAAPEADGQAAGALASRNTHSAELPPPDQPSPCKCTCKKEPSSVSPSATVKTRSTKAPPPHLPLSPALTRAVEGVQYIADHLKAEDTDFSVKEDWKYVAMVIDRIFLWMFIIVCLLGTVGLFLPPWLAGMI
-
分子量
69.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Research on the recombinant CHRNA4 protein primarily focuses on its role as a subunit of the nicotinic acetylcholine receptor (nAChR), a critical component in neuromuscular transmission and neurotransmission in the central nervous system. The CHRNA4 gene encodes the alpha-4 subunit, which pairs with beta subunits to form functional receptors that mediate the effects of acetylcholine, influencing processes such as cognition, reward, and muscle contraction. Abnormalities in CHRNA4 expression or function have been linked to various neurological disorders, including schizophrenia, Alzheimer's disease, and addiction. As a result, CHRNA4 has garnered interest as a potential therapeutic target. Recombinant CHRNA4 proteins can be produced to study their structural properties, pharmacological profiles, and interaction with various ligands. This research is essential for understanding receptor function, developing novel drugs, and assessing potential treatments for diseases associated with cholinergic system dysfunction. Furthermore, investigations into the post-translational modifications and cellular trafficking of the recombinant CHRNA4 protein can provide deeper insights into its role in health and disease. Overall, the study of recombinant CHRNA4 protein represents a significant avenue for advancing our comprehension of neurobiology and addressing unmet medical needs.
